Relatlimab/Nivolumab Improves PFS in Previously Untreated Metastatic or Unresectable Melanoma

Source: OncLive, March 2021

The fixed-dose combination of relatlimab plus nivolumab (Opdivo) was found to improve progression-free survival (PFS) over nivolumab alone in patients with previously untreated metastatic or unresectable melanoma, meeting the primary end point of the phase 2/3 RELATIVITY-047 (CA224-047; NCT03470922) trial.1

Relatlimab is an anti-LAG-3 antibody, and these phase 3 data are the first to be reported from a trial evaluating such an agent, according to Bristol Myers Squibb, the drug developer.

READ THE ORIGINAL FULL ARTICLE